Kiniksa Pharmaceuticals develops and sells ARCALYST, a treatment for recurrent pericarditis and other inflammatory conditions. It last closed at $93.89 on Nov 20, up 0.38% on the day. The next earnings report for KNSA is expected around Mon, Jan 11, 2027, after the close. For the quarter ended Sep 2026, KNSA reported EPS of $0.56 on revenue of $286.0M, with revenue up 58.1% from a year ago. Over its last 8 reports the stock moved an average of 15.1% the session after earnings. Over the last 12 months KNSA insiders bought $0 of stock on the open market and sold $121.7M, according to SEC Form 4 filings.
AI Auto Pilots
Is KNSA in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold KNSA.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on KNSAStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
KNSA · as of the Nov 20 close · updated each morning
Uptrend
The stock is 1% above its 20 day and 11% above its 50 day average. It is 32% above its 200 day average, so the longer trend is still up. Momentum is neutral (RSI 56). The nearest support is the 20 day average at $93.18, and the nearest resistance the Pivot at $93.95.
Short trendBullish
Long trendBullish
MomentumNeutral
StretchNormal
VolatilityNormal, 4.3%/day
Key levels
$99.3152 week high+5.8%
$97.96Swing high (Nov 16)+4.3%
$95.23Pivot R1+1.4%
$93.95Pivot+0.1%
$93.89Last close
$93.1820 day average−0.8%
$92.62Pivot S1−1.4%
$87.30Swing low (Nov 5)−7.0%
$83.8950 day average−10.7%
$78.48100 day average−16.4%
$64.09200 day average−31.7%
$37.0252 week low−60.6%
Indicators
RSI (14)
55.81
Middle of its range
Neutral
MACD
3.25
Below its signal line
Bearish
Stochastic
57.1
Middle of its range
Neutral
ADX (14)
20.6
Weak trend
Williams %R
-45.1
Oversold below −80, overbought above −20
Neutral
CCI (20)
20.6
Oversold below −100, overbought above 100
Neutral
Rate of change
+0.0%
Change over 10 sessions
Bullish
ATR (14)
$4.05
Typical daily range, 4.3% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Above
MA 200Above
Uptrend, overbought
Short trendBullish
Long trendBullish
MomentumStrong
StretchOverbought
VolatilityNormal, 7.5%/day
Key levels
$99.3152 week high+5.8%
$97.96Swing high (Nov 16)+4.3%
$95.23Pivot R1+1.4%
$93.95Pivot+0.1%
$93.89Last close
$93.1820 day average−0.8%
$92.62Pivot S1−1.4%
$87.30Swing low (Nov 5)−7.0%
$83.8950 day average−10.7%
$78.48100 day average−16.4%
$64.09200 day average−31.7%
$37.0252 week low−60.6%
Indicators
RSI (14)
75.13
Overbought above 70
Overbought
MACD
9.41
Above its signal line
Bullish
Stochastic
84.7
Near the top of its range
Overbought
ADX (14)
50.2
Strong uptrend
Williams %R
-18.9
Oversold below −80, overbought above −20
Overbought
CCI (20)
179.5
Oversold below −100, overbought above 100
Overbought
Rate of change
+23.1%
Change over 10 sessions
Bullish
ATR (14)
$7.08
Typical daily range, 7.5% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for KNSA
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how KNSA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow KNSA usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for KNSAHow many large options trades hit KNSA, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in KNSA in the last 90 days.
From SEC Form 4 filings by KNSA's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether KNSA is in one of them and how their past KNSA trades turned out.
Kiniksa Pharmaceuticals is a drug developer based in London that focuses on cardiovascular diseases. Its main product, ARCALYST, is approved in the United States for recurrent pericarditis, an inflammatory condition of the heart lining, and for certain autoinflammatory syndromes. The company sells ARCALYST in the United States through specialty pharmacies, has licensed partners in other regions, and is developing KPL-387, an investigational antibody that targets the same inflammation pathway. Its customers are patients and the doctors who treat them.